# Saras Capital

> Saras Capital is a VC fund in England backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: England, Germany
- Total investments: 11
- Last investment: Jan 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/saras-capital/
- Website: https://www.sarascapital.com/

Saras Capital is an a investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 82% |
| Health Care | 3 | 27% |
| Artificial Intelligence | 3 | 27% |
| Medical | 2 | 18% |
| Therapeutics | 2 | 18% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 82% |
| Series A | 1 | 9% |
| Series C | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 27% |
| United Kingdom | 3 | 27% |
| France | 2 | 18% |
| Germany | 1 | 9% |
| Ireland | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Converge Bio | Converge Bio integrates Generative AI with biological data. Converge Bio mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages. | $25M | Series A | Jan 13, 2026 |  |
| Biographica | Biographica is a computational biology company that develops software tools and platforms to support genomic data analysis, interpretation, and visualization for research and clinical applications. Its solutions are designed to help scientists, clinicians, and bioinformaticians process complex genomic datasets, annotate genetic variants, andexplore biological insights through integrated workflows and interactive visualizations. The company’s platform combines data management, algorithmic analysis, and graphical interfaces to streamline tasks such as sequence alignment, variant calling, functional interpretation, and cohort comparison. Biographica’s tools support interoperability with common bioinformatics formats and pipelines, enabling users to integrate genomic workflows with existing research infrastructure. The company also provides APIs and developer tools to allow custom integration, automation, and extension of analytic capabilities within broader computational environments. Its offerings are used across life sciences research, translational projects, and precision medicine initiatives that require scalable, interpretable genomic data analysis. | $9.5M | Seed | Jan 07, 2026 |  |
| Cellbyte | Cellbyte is an AI based firm that offers safety and security standards for pharma companies to provide life-changing treatments to patients. | $2.8M | Seed | Nov 18, 2025 |  |
| Modulight Bio | Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders. The company’s technology uses optogenetics to modulate neuronal activity by targeting synaptic mechanisms. Its approach relies on endogenous cellular processes to adjust neural signaling with spatial and temporal precision. The platform is designedto address conditions associated with abnormal or excessive neuronal activation. | $12M | Seed | Nov 13, 2025 |  |
| Valink Therapeutics | Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M | Seed | Oct 20, 2025 |  |
| Aerska | Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $21M | Seed | Oct 01, 2025 |  |
| Kyron.bio | Kyron.bio uses the power of glycan alterations to enable improved protein therapies. | $6.2M | Seed | May 28, 2025 |  |
| Generare | Generare is a biotech startup that discovers next-generation medicines and high-value molecules hiding in soil bacteria. | $5.5M | Seed | Oct 07, 2024 |  |
| Infinitopes | Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $16M | Seed | Apr 30, 2024 |  |
| Parse Biosciences | Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $50M | Series C | Dec 14, 2023 |  |

10 of 11 investments shown.

## Co-investors
- [SynBioVen](https://shizune.co/investors/profile/synbioven) — VC Fund, 3 deals together
- [Entrepreneurs First](https://shizune.co/investors/profile/entrepreneurs-first) — VC Fund, 2 deals together
- [Ada Ventures](https://shizune.co/investors/profile/ada-vemtires) — VC Fund, 1 deal together
- [age1](https://shizune.co/investors/profile/age-1) — VC Fund, 1 deal together
- [BACKED VC](https://shizune.co/investors/profile/backed-vc) — VC Fund, 1 deal together
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Ireland](https://shizune.co/investors/biotechnology-vc-funds-ireland)
- [Biotech Investors in Ireland](https://shizune.co/investors/biotech-investors-ireland)
- [Biotech VC Funds in Ireland](https://shizune.co/investors/biotech-vc-funds-ireland)

## FAQ

### What does Saras Capital invest in?

Saras Capital invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Saras Capital last invest?

The most recent investment recorded for Saras Capital closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co